Getinge (DB:GTN) - Stock Price, News & Analysis

GTN Stock Overview

Provides products and solutions for operating rooms, intensive-care units, and sterilization departments. More details

GTN fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 56.2% below our estimate of its fair value

Earnings are forecast to grow 22.02% per year

Risk Analysis

Unstable dividend track record

Profit margins (5%) are lower than last year (7.4%)

Getinge AB (publ) Competitors

Carl Zeiss Meditec

XTRA:AFX

€5.2b

Eckert & Ziegler

XTRA:EUZ

€795.9m

Drägerwerk KGaA

XTRA:DRW3

€792.7m

Siemens Healthineers

XTRA:SHL

€55.0b

Price History & Performance

Summary of all time highs, changes and price drops for Getinge
Historical stock prices
Current Share Price	SEK 15.56
52 Week High	SEK 20.85
52 Week Low	SEK 15.56
Beta	0.49
11 Month Change	-14.13%
3 Month Change	-13.05%
1 Year Change	-18.58%
33 Year Change	-58.92%
5 Year Change	-0.77%
Change since IPO	42.75%

Recent updates

Shareholder Returns

	GTN	DE Medical Equipment	DE Market
7D	-7.7%	-3.7%	-0.5%
1Y	-18.6%	-4.2%	8.3%

Return vs Industry: GTN underperformed the German Medical Equipment industry which returned -4.2% over the past year.

Return vs Market: GTN underperformed the German Market which returned 8.3% over the past year.

Price Volatility

Is GTN's price volatile compared to industry and market?
GTN volatility
GTN Average Weekly Movement	3.6%
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: GTN has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: GTN's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1904	11,848	Mattias Perjos	www.getinge.com

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions.

Getinge AB (publ) Fundamentals Summary

How do Getinge's earnings and revenue compare to its market cap?
GTN fundamental statistics
Market cap	€4.06b
Earnings (TTM)	€146.17m
Revenue (TTM)	€2.90b

27.8x

P/E Ratio

1.4x

P/S Ratio

Is GTN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GTN income statement (TTM)
Revenue	SEK 33.59b
Cost of Revenue	SEK 18.21b
Gross Profit	SEK 15.39b
Other Expenses	SEK 13.69b
Earnings	SEK 1.69b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 28, 2025

Earnings per share (EPS)	6.21
Gross Margin	45.80%
Net Profit Margin	5.03%
Debt/Equity Ratio	30.0%

How did GTN perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

71%

Payout Ratio

GTN Stock Overview

Rewards

Risk Analysis

Getinge AB (publ) Competitors

XTRA:AFX

€5.2b

XTRA:EUZ

€795.9m

XTRA:DRW3

€792.7m

XTRA:SHL

€55.0b

Price History & Performance

Recent News & Updates

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Third quarter 2024 earnings released: EPS: kr0.007 (vs kr3.28 in 3Q 2023)

Independent Director recently bought €98k worth of stock

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Independent Chairman recently bought €375k worth of stock

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Recent updates

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Third quarter 2024 earnings released: EPS: kr0.007 (vs kr3.28 in 3Q 2023)

Independent Director recently bought €98k worth of stock

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Independent Chairman recently bought €375k worth of stock

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Second quarter 2024 earnings released: EPS: kr1.88 (vs kr0.79 in 2Q 2023)

New minor risk - Share price stability

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Investor sentiment deteriorates as stock falls 17%

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Dividend of kr4.40 announced

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Full year 2023 earnings released: EPS: kr8.86 (vs kr9.15 in FY 2022)

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

Third quarter 2023 earnings released

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Second quarter 2023 earnings released

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Investor sentiment deteriorates as stock falls 16%

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

First quarter 2023 earnings released

Now 23% undervalued

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Full year 2022 earnings released: EPS: kr9.15 (vs kr10.90 in FY 2021)

Getinge AB (Publ) Proposes Dividend

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Third quarter 2022 earnings released

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Second quarter 2022 earnings released: EPS: kr2.21 (vs kr2.93 in 2Q 2021)

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

Investor sentiment deteriorated over the past week

Getinge Revises Net Sales Guidance for the Full Year 2022

Independent Chairman recently bought €281k worth of stock

Insufficient new directors

Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022

Upcoming dividend of kr4.00 per share

Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022

Full year 2021 earnings released: EPS: kr10.90 (vs kr11.89 in FY 2020)

Insufficient new directors

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.

Chief Commercial Officer recently bought €56k worth of stock

Third quarter 2021 earnings released